T1	Participants 294 353	multicenter, double-blind, randomized, parallel-group study
T2	Participants 647 815	patients in Cycles 2 and 3, respectively, for the 10 micrograms/kg group, and in 42% and 38% of patients in Cycles 2 and 3, respectively, for the 40 micrograms/kg group
